Management believes that this transaction will provide Regenicin adequate funding to continue product development of life saving technology. It is estimated that the proceeds should bring us to the initiation of FDA sanctioned clinical trials with our first cell therapy wound care product.

Thats awesome. So Amarantus paid Regenicin money so that they could turn around and just make another version of the skin graft. Probably knew that AMBS had no money and would eventually bury themselves, leaving the market open to their new product NovaDerm. Would not surprise me in the least that Gerald would be that clueless. Pay a competitor to help them create the competing product. Did I miss something?